Mersana Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
April 28 2021 - 4:05PM
Mersana Therapeutics, Inc. (Nasdaq: MRSN), a clinical-stage
biopharmaceutical company focused on discovering and developing a
pipeline of antibody-drug conjugates (ADCs) targeting cancers in
areas of high unmet medical need, today announced the grant of an
inducement award to the newly appointed Senior Vice President and
Chief Legal Officer, Alejandra Carvajal. In connection with the
appointment, the Compensation Committee of the Board of Directors
of Mersana Therapeutics approved a stock option grant to Ms.
Carvajal as an inducement material to Ms. Carvajal entering into
employment with Mersana Therapeutics, in accordance with Nasdaq
Listing Rule 5635(c)(4). The stock option grant provides for the
purchase of up to 112,500 shares of Mersana Therapeutics common
stock, at a price of $16.98 per share, the closing price per share
of Mersana Therapeutics common stock on the date of grant, and
vests over four years, with 25% of the shares vesting on the first
anniversary of the Ms. Carvajal’s employment start date, and the
remainder vesting in equal quarterly installments over the
following three years, subject to Ms. Carvajal’s continued
employment with Mersana Therapeutics through such applicable
vesting dates.
About Mersana
TherapeuticsMersana Therapeutics is a clinical-stage
biopharmaceutical company using its differentiated and proprietary
ADC platforms to rapidly develop novel ADCs with optimal efficacy,
safety and tolerability to meaningfully improve the lives of people
fighting cancer. Mersana’s lead product candidate, upifitamab
rilsodotin (UpRi), is a Dolaflexin ADC targeting NaPi2b and is
being studied in UPLIFT, a single-arm registration strategy, in
patients with platinum-resistant ovarian cancer as well as the
expansion portion of a Phase 1 proof-of-concept clinical study in
patients with NSCLC adenocarcinoma. XMT-1592, Mersana’s second ADC
product candidate targeting NaPi2b-expressing tumors, was created
using Mersana’s customizable and homogeneous Dolasynthen platform
and is in the dose escalation portion of a Phase 1 proof-of-concept
clinical study. The Company’s early-stage programs include
XMT-1660, a Dolasynthen ADC targeting B7-H4, as well as XMT-2056, a
STING-agonist ADC developed using the Company’s Immunosynthen
platform. In addition, multiple partners are using Mersana’s
Dolaflexin platform to advance their ADC pipelines.
Contact:
Investor & Media ContactSarah
Carmody, 617-844-8577scarmody@mersana.com
Mersana Therapeutics (NASDAQ:MRSN)
Historical Stock Chart
From Aug 2024 to Sep 2024
Mersana Therapeutics (NASDAQ:MRSN)
Historical Stock Chart
From Sep 2023 to Sep 2024